Cerebral white matter demyelinating disease is clinically categorized into three levels, with Grade I changes being less severe, and Grade II and Grade III changes being relatively more severe. Grade I white matter demyelination is mostly due to ischemia and hypoxia of the cerebral white matter, resulting in malnutrition, and the patient has no clinical symptoms. Secondary and tertiary changes in cerebral white matter demyelination are generally considered to be due to severe ischemia and hypoxia, and as the disease progresses and worsens, people may experience memory loss and, in severe cases, slowed reaction time. The main treatment is to improve the nutritional status of the white matter of the brain, and at the same time to avoid smoking, drinking and other risk factors that can increase cerebral atherosclerosis. If the patient’s memory loss is more obvious, it can be appropriate to take oral drugs to improve the metabolism of brain cells, commonly used in the clinic, such as olanzapine, piracetam, cerebral protein hydrolyzate tablets, cytosine sodium tablets and so on.